What Is Sleep Apnea

Sleep apnea is a disorder characterized by repeated pauses in breathing during sleep, each lasting at least ten seconds and occurring many times per hour. These pauses cause drops in blood oxygen, micro-arousals from sleep, and surges of stress hormones. The most common form, obstructive sleep apnea, results from physical collapse of the upper airway, while central sleep apnea stems from impaired brain signaling to the muscles of respiration.

Sleep apnea sits at the intersection of nearly every major aging pathway. Each breathing cessation triggers an oxygen desaturation event followed by re-oxygenation, creating a cycle analogous to repeated ischemia-reperfusion injury. This generates oxidative stress, activates nuclear factor kappa-B (NF-kB) mediated inflammation, and drives sympathetic nervous system overactivation that persists into waking hours. The cumulative effect is a body that operates under chronic physiological stress even when subjectively unaware of poor sleep quality.

The downstream consequences touch cardiovascular health, metabolic regulation, and brain integrity simultaneously. Epidemiological data associate untreated moderate to severe sleep apnea with a substantially higher incidence of hypertension, atrial fibrillation, stroke, type 2 diabetes, and cognitive decline. Sleep fragmentation also impairs glymphatic clearance, the brain's waste-removal system that depends on sustained deep sleep to flush amyloid-beta and tau proteins. For anyone pursuing healthspan extension, undiagnosed or untreated sleep apnea can quietly undermine every other intervention.

During normal sleep, the muscles of the upper airway maintain enough tone to keep the pharynx open. In obstructive sleep apnea, these muscles relax excessively, allowing the soft palate, tongue base, and surrounding tissue to collapse inward and obstruct airflow. The diaphragm and chest wall continue to make breathing efforts against the closed airway, but no air moves. After seconds to over a minute, the resulting drop in oxygen and rise in carbon dioxide triggers a brainstem arousal reflex. The sleeper partially wakes, airway tone is restored, and breathing resumes, usually with a gasp or snort. This cycle can repeat dozens or hundreds of times per night.

Each event produces a cascade of acute physiological changes. Oxygen saturation can fall into the 70s or 80s (percent), activating chemoreceptors that spike sympathetic outflow. Heart rate and blood pressure surge. Cortisol and catecholamines flood the bloodstream. The intermittent hypoxia also stabilizes hypoxia-inducible factor (HIF-1 alpha) in a maladaptive pattern, promoting vascular inflammation and endothelial dysfunction rather than the adaptive responses seen in controlled altitude exposure. Over time, the endothelium stiffens, atherosclerotic plaques progress faster, and insulin sensitivity deteriorates.

The brain suffers through two parallel mechanisms. First, repeated arousals prevent the sleeper from sustaining the deep slow-wave and REM sleep stages required for memory consolidation, hormonal regulation, and glymphatic function. Growth hormone secretion, which depends on consolidated slow-wave sleep, is blunted. Second, the intermittent hypoxia directly injures neurons in oxygen-sensitive regions such as the hippocampus and prefrontal cortex. Neuroimaging studies in people with untreated sleep apnea consistently show gray matter volume reductions in these regions, correlating with measurable cognitive deficits in attention, executive function, and memory.

The association between obstructive sleep apnea and cardiovascular disease is supported by decades of epidemiological research and prospective cohort studies. Observational data consistently show that untreated moderate to severe obstructive sleep apnea increases the risk of hypertension, coronary artery disease, atrial fibrillation, stroke, and cardiovascular mortality. The relationship with metabolic disease is similarly well established: sleep apnea independently worsens insulin resistance and is a recognized contributor to type 2 diabetes risk. Neuroimaging studies have documented gray matter volume loss and white matter changes in individuals with untreated apnea, and cognitive testing reveals deficits in memory, attention, and executive function that partially reverse with treatment.

The evidence for CPAP therapy specifically is more nuanced than often presented. While observational studies suggest that consistent CPAP use is associated with reduced cardiovascular events and mortality, several large randomized controlled trials in patients with established cardiovascular disease have not shown a statistically significant reduction in major cardiovascular events with CPAP. These trials are limited by poor adherence (average use often fell below four hours per night) and by enrolling populations with existing disease rather than studying primary prevention. The weight of evidence supports meaningful benefits in blood pressure reduction, daytime function, and quality of life. Research into hypoglossal nerve stimulation has expanded treatment options for those who cannot tolerate CPAP, with multiple controlled trials demonstrating significant AHI reductions. Studies on the link between sleep apnea and accelerated biological aging, measured via epigenetic clocks, are emerging but remain preliminary.

Untreated sleep apnea carries significant health risks, but the treatments themselves have considerations worth noting. CPAP therapy can cause nasal dryness, mask discomfort, aerophagia, and claustrophobia, leading to abandonment rates that remain high across studies. Oral appliances may cause temporomandibular joint discomfort and gradual changes in dental occlusion over years of use. Surgical interventions carry the standard risks of anesthesia and procedure-specific complications, with variable long-term success rates. Over-reliance on positional therapy or weight loss alone may leave residual apnea that continues to cause harm. Any treatment plan benefits from objective follow-up testing to confirm that the apnea-hypopnea index has been adequately reduced.